Definium Therapeutics releases Phase 3 Emerge topline results presentation for DT120 in MDD

Definium Therapeutics, Inc.

Definium Therapeutics, Inc.

DFTX

0.00
  • Definium Therapeutics published Phase 3 Emerge topline results for DT120 ODT in major depressive disorder.
  • Primary endpoint met, showing an 8.1-point MADRS improvement over placebo at week 6 (p<0.0001); 7.3 points at week 12 (p<0.0001).
  • Key secondary endpoint met, with a 0.9-point CGI-S improvement over placebo at day 2 (p<0.0001).
  • Safety profile showed no serious adverse events, no suicidality signal, no discontinuations; 99% reported a treatment-emergent adverse event.
  • Trial randomized 149 patients; single-dose DT120 ODT 100 micrograms versus placebo with outcomes tracked through 12 weeks.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Definium Therapeutics Inc. published the original content used to generate this news brief on June 22, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.